Sign in
Taking people in United StatesPhase 1

Effect of Sublingual Formulation of Dexmedetomidine Hydrochloride (HCl) (BXCL501) - Outpatient Study

Key facts

Who runs it
Pharmacotherapies for Alcohol and Substance Use Disorders Alliance
Where
West Haven, United StatesSee the site
Trial code
Status
Recruiting
Phase
Phase 1
People taking part
10 people, planned
Started
28 Jul 2025
Expected to end
30 Apr 2027
Type of study
Interventional
Treatments tested
  • Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg
  • Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg
Record updated
21 September 2026

Who can take part

Age
21 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • Veterans and non-Veterans, ages 21 to 65
  • Able to read and write in English and sign the informed consent
  • Willing to comply with all study procedures and be available for the duration of the study
  • ECG that demonstrates no clinically significant conduction issues or arrhythmias
  • Have no clinically significant contraindications, in the judgement of the PI/study physician, for study participation (based on self-reported medical history and brief physical examination)
  • Have a current diagnosis of Alcohol use disorder (AUD) (mild, moderate, or severe) as determined by MINI-5
  • Have a lifetime traumatic event in their lifetime that meets Criterion A for PTSD as determined by screening interview and the MINI-5
  • Have a PCL-5 score > 15 prior to starting the study medication
  • Must have > 1 heavy drinking episodes (>4 standard drink units (SDU) for men; >3 SDU for women) in the last 30 days (assessed by the Timeline Follow Back (TLFB))
  • Females of childbearing potential (not surgically sterilized (tubal ligation/hysterectomy) or not post-menopausal (no menstrual period for > 6 months)) must be willing to use a medically acceptable and effective birth control method for 1 month before the study and while participating in the study. Medically acceptable methods of contraception that may be used by the participant include abstinence, birth control pills or patches, birth control implants, diaphragm, intrauterine device (IUD), or condoms

Who cannot take part

  • Currently taking the following medications: a) medications for alcoholism (e.g. naltrexone, disulfiram, topiramate, acamprosate); b) psychotropic medications that promote sedation including sedative/hypnotics, barbiturates, antihistamines, sedative antidepressants (e.g. doxepin, mirtazapine, trazodone), and triptans (e.g., sumatriptan); c) antihypertensive medications; d) alpha-2-adrenergic agonists (clonidine, guanfacine, lofexidine); or adrenergic agents prescribed for other reasons are excluded (prazosin). (Permitted Concomitant Medications: The concomitant medications allowed in the study include non-sedative antidepressants used to treat PTSD)
  • Participation in a clinical trial of a pharmacological agent within 30 days prior to screening
  • Current bipolar disorder or psychotic disorders as determined by MINI-5
  • Current diagnosis of a substance use disorder (other than alcohol, nicotine, or marijuana) as determined by MINI-5
  • Recent history of complicated alcohol withdrawal, alcohol withdrawal seizures, or delirium tremens (DTs)
  • History of major medical illnesses including liver disease, heart disease, chronic pain or other medical conditions that the physician investigator deems contraindicated for the participant to be in the study
  • History of allergic reactions to dexmedetomidine or known allergy to dexmedetomidine
  • Clinically significant history of cardiac disease including (a) chronic hypertension (even if adequately controlled by antihypertensive medications); (b) history of syncope or other syncopal attacks; (c) current evidence of orthostatic hypotension (defined as a decrease in systolic BP of 20 mm Hg or decrease in diastolic BP of 10mm Hg within 3 minutes); (d) resting heart rate of <55 beats per minute; (e) systolic blood pressure <110mmHg or diastolic BP <70mmHg; or (f) participants with a QTC interval >440msec (males) or >460msec (females)
  • Clinically significant medical conditions including hepatic (ascites, bilirubin >10% above the upper limit of normal [ULN] or liver function tests [LFT] >3 × ULN)
  • Renal impairment as measured by BUN/Creatinine
  • Females who are pregnant, nursing, or planning to become pregnant during study participation
  • Current physiological alcohol dependence requiring a higher level of care (e.g., detox) as determined by study physician conducting physical examination and CIWA score. Tolerance to alcohol will be allowed
  • Score > 4 on Clinical Institute Withdrawal Assessment for Alcohol Scale (CIWA-Ar) at screening
  • Any finding that, in the view of the principal investigator, would compromise the subject's ability to fulfill the study visit schedule or requirements

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 21 and 65 years old?

Where in United States

  • VA Connecticut Healthcare SystemWest Haven, United StatesContact: Jenelle Newcomb, BATaking people

About the trial

What the trial wants to find out

The overall objective of the proposed study is to determine if Dexmedetomidine HCl (BXCL501) is safe for treatment of alcohol use disorder (AUD) with comorbid posttraumatic stress disorder (PTSD) in an outpatient setting and also shows potential signals of efficacy thereby supporting the conduct of later phase clinical trials.

The group in the trial

  • BXCL501 Dose Range 40µg to 160µgOther group

    Participants will receive 40µg on days 1-2. On days 3 and 4, participants will receive 40µg twice per day. On days 5 and 6 participants will receive 40µg in the morning and 80µg in the evening. On days 7-28 participants will receive 80µg in the morning and evening. Dose escalation will follow the above schedule based on tolerability assessed by clinician.

    Treatment: Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg and Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Effect of Sublingual Formulation of Dexmedetomidine HCl (BXCL501) on Ethanol in Heavy Drinkers With PTSD - Outpatient Study
Fit questions
Built from NCT06335407, who can take part
Record updated
21 September 2026